Health Press Release – Newsletter for December 18, 2010

InterMune Announces Positive Opinion for Approval of Esbriet(TM) (Pirfenidone) in European Union

BRISBANE, California, December 17, 2010 – — Esbriet to be the first medicine approved for IPF patients in the EU –

InterMune, Inc. (Nasdaq: ITMN) today announced that the Committee for
Medicinal Products for Human Use (CHMP) of the European Medicines Agency
(EMA) has adopted a positive opinion recommending the granting of a …. Original article  : InterMune Announces Positive Opinion for Approval of Esbriet(TM) (Pirfenidone) in European Union.

InspireMD Celebrates Successful ICI 2010 Meeting; Long-Term Data Validates MGuard as Potentially Important Tool in Modern Acute MI Therapy

Distinguished Panel Chaired by Dr. Martin B. Leon, From Columbia University Medical Center, Discuss Advancement of MGuard

TEL AVIV, Israel, December 17, 2010 – InspireMD, developer of the novel MGuard(TM), a combination of
a coronary stent merged with an embolic protection specifically designed for
Acute MI (AMI) patients, received significant exposure at the ICI,
Innovations in Interventional Cardiology, … Read the original article on Gaea Times at : InspireMD Celebrates Successful ICI 2010 Meeting; Long-Term Data Validates MGuard as Potentially Important Tool in Modern Acute MI Therapy.

InterMune Announces Senior Leadership Appointments to Prepare for Launch of Esbriet(TM) (Pirfenidone) in Europe

BRISBANE, California, December 17, 2010 – — Conference call and webcast today at 8:30 a.m. EST to discuss positive
CHMP opinion –

InterMune, Inc. (Nasdaq: ITMN) today announced additions to its senior
leadership team to prepare for the commercialization of Esbriet(TM)
(pirfenidone) in Europe. InterMune's Marketing Authorization Application
(MAA) for Esbriet received a positive CHMP …. Original article on Gaea Times at  : InterMune Announces Senior Leadership Appointments to Prepare for Launch of Esbriet(TM) (Pirfenidone) in Europe.

Teysuno(TM) (S-1) Receives CHMP Positive Opinion for Approval as First-Line Therapy for Advanced Gastric Cancer

Recommendation Marks Taiho's First Regulatory Milestone Outside of Japan and Asia

TOKYO, December 17, 2010 – Taiho Pharmaceutical Co., Ltd., and its parent company, Otsuka Holdings
Co., Ltd., announced today that the Committee for Medicinal Products for
Human Use (CHMP), a division of the European Medicines Agency (EMA), has
issued an opinion recommending approval of Teysuno(TM) (S-1), a …. Original article on Gaea Times at  : Teysuno(TM) (S-1) Receives CHMP Positive Opinion for Approval as First-Line Therapy for Advanced Gastric Cancer.